Hypothesis

Enhancing mitochondrial quality control in hematopoietic stem cells (HSCs) interrupts the immune‑driven aging loop by limiting the release of mitochondrial damage‑associated molecular patterns (mtDAMPs) that accelerate stromal senescence.

Mechanistic rationale

Senescent immune cells accumulate damaged mitochondria that leak mtDNA and reactive oxygen species into the circulation [https://doi.org/10.1038/s41586-021-03547-7]. These mtDAMPs activate cytosolic DNA‑sensing pathways in stromal cells, depleting NAD+ and triggering a senescent phenotype that spreads fibrosis and organ dysfunction. Conversely, young immune cells keep mitochondrial turnover high through PINK1‑Parkin mediated mitophagy, keeping circulating mtDAMPs low.

We propose that genetic or pharmacologic boosting of mitophagy specifically in HSCs will:

• Reduce circulating mtDNA and ROS levels.
• Preserve NAD+ in stromal compartments.
• Delay the accumulation of senescent stromal cells across multiple tissues.
• Extend healthspan without directly clearing senescent cells.

Testable predictions

1. Mice with hematopoietic‑specific overexpression of PINK1 (or Parkin) will show lower plasma mtDNA and ROS compared with littermate controls.
2. These mice will exhibit reduced p16^Ink4a^ and SASP expression in liver, kidney, and adipose tissue despite having the same burden of senescent hematopoietic cells.
3. Frailty indices, grip strength, and glucose tolerance will improve significantly in mid‑life, and median lifespan will increase by at least 15%.
4. Transplant of wild‑type bone marrow into irradiated recipients will not confer the protective effect, confirming that the benefit is cell‑autonomous to the hematopoietic compartment.

Falsifiability

If hematopoietic‑specific mitophagy enhancement fails to lower circulating mtDAMPs, does not reduce stromal senescence markers, and does not improve frailty or lifespan, the hypothesis is refuted. Likewise, if systemic benefits are abolished by NAD+ supplementation in stromal cells, it would suggest that mtDAMPs act upstream of NAD+ depletion, supporting the mechanism; if benefits persist despite NAD+ blockade, the proposed pathway would be questioned.

Experimental approach

• Generate Vav‑Cre; Rosa26^LSL‑PINK1^ mice (HSC‑specific PINK1 overexpression).
• Validate mitophagy flux using mt‑Keima in bone marrowderived macrophages.
• Measure plasma mtDNA by qPCR, ROS by Amplex Red, NAD+ levels in tissue extracts.
• Quantify senescence via p16^Ink4a^ immunostaining and SASP cytokine arrays.
• Conduct longitudinal frailty monitoring and survival analysis.
• Perform bone‑marrow transplant experiments to test cell autonomy.

Potential impact

Demonstrating that fixing mitochondrial health in immune cells can slow aging shifts the focus from senolysis to prevention of immune‑derived mitochondrial damage. It offers a complementary strategy that may be safer for long‑term use because it enhances a physiological quality‑control system rather than removing cells.